Drug Dollars Seek to Convince Doctors That 2nd Choice Is OK

Updated on

U.S. doctors and hospitals received more than $20 million last year in payments related to AstraZeneca Plc’s diabetes drug Bydureon, more than for any other medication, newly released company disclosures show.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.